Latest News & Updates
George D. Demetri, MD, expands on the challenges with overall survival as a primary outcome measure, the potential of trabectedin in soft tissue sarcomas, and the significance of a recent trial.
The FDA has granted the CDK4/6 inhibitor abemaciclib a breakthrough therapy designation as monotherapy for heavily pretreated patients with refractory hormone-receptor-positive advanced breast cancer.
Examples of the clinical relevance of an individual patient’s normal polymorphisms continue to mount.
Encouraging findings and regulatory milestones have recently been announced for the PD-1 inhibitor pembrolizumab and the PD-L1 inhibitor avelumab as treatments for patients with metastatic Merkel cell carcinoma.
The jury is still out on whether use of an algorithm to help classify risk levels in ovarian cancer can improve overall survival but a company is already marketing the system in Britain and plans to bring it to the United States before the end of the year.
Latest Peer Exchange Discussions
Kenneth Anderson, MD, reviews the newest generation of medications used in the treatment of relapsed multiple myeloma. View Now
Dirk Arnold, MD, PhD, and Fortunato Ciardiello, MD, PhD, discuss the use of regorafenib and TAS-102 in previously treated metastatic colorectal cancer. View Now
Michael Kolodziej, MD, and Jeffrey C. Ward, MD, discuss balancing treatment decisions while also taking health plan coverage into consideration. View Now
Most Popular Right Now
Online CME Activities